Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bufferin, Excedrin sale in Asia

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb plans to sell its Bufferin and Excedrin pain relief brands in Asia (excluding China and Taiwan) and certain Oceanic countries to Japanese firm Lion Corporation for approximately $250 mil. (¥30.4 bil.), BMS announces June 29. Expected to close during the third quarter pending regulatory approvals, the deal will allow BMS to "focus on its strategic priorities in developing its pipeline and new product opportunities in disease areas of significant unmet need," the firm notes. BMS sold its Consumer Medicines businesses, including the Bufferin and Excedrin brands, in the U.S., Canada and other markets to Novartis AG in 2005 (1"The Tan Sheet" Sept. 5, 2005, In Brief). In a separate agreement, BMS and Lion have agreed to the dissolution of the firms' medicines joint venture...

You may also be interested in...



BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation

Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary

Bristol/Novartis deal

Bristol-Myers Squibb has completed the sale of its U.S. and Canadian Consumer Medicines business to Novartis AG, the firm announces Aug. 31. The transfer of the rights to Bristol's OTC brands in Latin America, Europe, the Middle East and Africa should be completed by the end of the year, Bristol says. Novartis adds the Excedrin analgesic line, Bufferin aspirin, No-Doz caffeine pills and others to its current U.S. OTC line-up of brands, which include the Theraflu cough/cold line and Maalox antacids. The sale was announced July 14 (1"The Tan Sheet," July 18, 2005, p. 3)...

Lilly Looks To Accelerate Tirzepatide Into Obesity With Rolling Submission

Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel